Prashanth Ashok Kumar, MD, Upstate University Hospital, Syracuse, NY, shares his highlights from the San Antonio Breast Cancer Symposium (SABCS) 2022, including an updated analysis of the Phase III RxPONDER (NCT01272037) trial that explored the differential effect of endocrine therapy versus chemotherapy followed by endocrine therapy on cognitive impairment in breast cancer, and new data on trastuzumab deruxtecan. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
